Mark Kelly, a Democratic Senate candidate in Arizona, is scheduled later this month to attend a high-dollar fundraiser hosted by one of the city’s top lobbying firms, despite his pledge not to take “a dime of corporate PAC money.”
With Monday marking the ninth anniversary of the Supreme Court’s landmark decision on Citizens United v. Federal Election Commission, first-term Rep. Gil Cisneros (D., Calif.) called on Congress to support campaign finance reform, despite his campaign benefitting from Democratic super PACs, special interest groups, and tens of thousands of dollars from the financial services industry.
Liberal billionaire George Soros has eclipsed a personal record amount on lobbying throughout the first three quarters of the year and has already spent $4 million more than he did throughout the entirety of last year—his previous yearly record—disclosure forms show.
The Associated Press confirmed a television advertisement released by the National Republican Senatorial Committee correctly pointed out Sen. Jon Tester (D., Mont.) “was No. 1 in Cash from Lobbyists in 2018.”
Sen. Bob Menendez’s (D., N.J.) campaign chairman works simultaneously as a lobbyist for the government of Qatar, raising concerns among some ethics experts about potential conflicts of interest.
Liberal billionaire George Soros’s nonprofit spent more on lobbying during the second quarter of 2018 than he has in any previous quarter, disclosure forms show.
Sen. Elizabeth Warren (D., Mass.), who has positioned herself as a crusader against corporate interests, received thousands of dollars from corporations, according to her latest FEC filing.
After multiple people central to Qatar’s efforts to win influence in the United States severed ties with the Persian Gulf country this week, influential U.S. lobbyists with connections to Doha have not said whether they plan to follow suit.
Former Democratic congressman Steven Horsford slammed the pharmaceutical lobby on Monday for “raking in record profits,” without mentioning he took over $70,000 in campaign contributions from the pharmaceutical industry while he was in office.
